drugset
drugset / Trial / NCT06179524

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

NCT06179524 ↗

Phase 2 Recruiting 100 enrolled Beijing Yongtai Ruike Biotechnology Company Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Timeline

Start
2024-01-03
Primary completion
2025-06-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisagenlecleucel Cell therapy 2.5e+06 cells/kg —

Indications

B-cell acute lymphoblastic leukemia